| |
Group 1 |
Group 2 |
Group 3 |
Group 4 |
p |
| Patient survival (%) |
93.3 |
96.4 |
94.4 |
92.5 |
0.696 |
| Death-uncensored graft survival (%) |
93.3 |
82.1 |
76.1 |
73.1 |
0.127 |
| Death-censored graft survival (%) |
86.7 |
78.6 |
70.4 |
65.4 |
0.086 |
| Acute rejection within 12 months after transplantation (%) |
33.3 |
14.3 |
38 |
31.3 |
0.200 |
| Cytomegalovirus infection within 12 months after transplantation (%) |
6.7 |
14.3 |
16.9 |
17.9 |
0.741 |
| eGFR 1 year after transplantation, mean ± SD (mL/min/1.73 m2) |
63.1 ± 13.9 |
60.4 ± 18.5 |
49.2 ± 15.3 |
42.6 ± 11.4 |
<0.001 |
| δeGFR, mean ± SD (mL/min/1.73 m2) |
26.5 ± 14.8 |
18.4 ± 16.5 |
29.4 ± 18.6 |
29.7 ± 13.2 |
0.016 |
